Tags

Type your tag names separated by a space and hit enter

Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy.
Acta Virol 2001; 45(1):39-44AV

Abstract

In 13 human immunodeficiency virus 1 (HIV-1) infected patients receiving a highly active antiretroviral therapy (HAART) annual influenza vaccination was conducted. It was hoped that HAART would prevent a post-vaccination increase in HIV-1 load and potential adverse effects. Only two patients had an increased viral load on day 14 post vaccination (p.v.). At 6 months p.v., the majority of the patients had a significantly increased CD4 cell count and a significantly decreased viral load. This indicates that HAART can protect patients from adverse consequences of influenza vaccination. The production of antibodies to the influenza A and B viruses in the HIV-infected patients was substantially lower than that in healthy persons. We propose that HIV-positive patients receiving HAART should be subjected to annual influenza vaccination.

Authors+Show Affiliations

Institute of Microbiology and Immunology, Medical Faculty, University of Ljubljana, Slovenia. srecko.koren@mf.uni-lj.siNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11394576

Citation

Banic, S, et al. "Influenza Vaccination of Human Immunodeficiency Virus 1-infected Patients Receiving Antiretroviral Therapy." Acta Virologica, vol. 45, no. 1, 2001, pp. 39-44.
Banic S, Koren S, Tomazic J, et al. Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy. Acta Virol. 2001;45(1):39-44.
Banic, S., Koren, S., Tomazic, J., Vidmar, L., Ihan, A., Poljak, M., & Avsic-Zupanc, A. (2001). Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy. Acta Virologica, 45(1), pp. 39-44.
Banic S, et al. Influenza Vaccination of Human Immunodeficiency Virus 1-infected Patients Receiving Antiretroviral Therapy. Acta Virol. 2001;45(1):39-44. PubMed PMID: 11394576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy. AU - Banic,S, AU - Koren,S, AU - Tomazic,J, AU - Vidmar,L, AU - Ihan,A, AU - Poljak,M, AU - Avsic-Zupanc,A, PY - 2001/6/8/pubmed PY - 2002/1/5/medline PY - 2001/6/8/entrez SP - 39 EP - 44 JF - Acta virologica JO - Acta Virol. VL - 45 IS - 1 N2 - In 13 human immunodeficiency virus 1 (HIV-1) infected patients receiving a highly active antiretroviral therapy (HAART) annual influenza vaccination was conducted. It was hoped that HAART would prevent a post-vaccination increase in HIV-1 load and potential adverse effects. Only two patients had an increased viral load on day 14 post vaccination (p.v.). At 6 months p.v., the majority of the patients had a significantly increased CD4 cell count and a significantly decreased viral load. This indicates that HAART can protect patients from adverse consequences of influenza vaccination. The production of antibodies to the influenza A and B viruses in the HIV-infected patients was substantially lower than that in healthy persons. We propose that HIV-positive patients receiving HAART should be subjected to annual influenza vaccination. SN - 0001-723X UR - https://www.unboundmedicine.com/medline/citation/11394576/Influenza_vaccination_of_human_immunodeficiency_virus_1_infected_patients_receiving_antiretroviral_therapy_ L2 - https://ClinicalTrials.gov/search/term=11394576 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -